文档介绍：替诺福韦酯在乙型肝炎母婴阻断中的合理应用
该论文来源于网络，本站转载的论文均是优质论文，供学****和研究使用，文中立场与本网站无关，版权和著作权归原作者所有，如有不愿意被转载的情况，请通知我们删除已转载的信息，如果需要分享，请保留本段说明。
[摘要] 目的 探讨替诺福韦酯阻断母婴垂直传播乙肝病毒（HBV）的疗效及安全性。 方法 随机选择2015年12月—2018年12月期间该院妇产科就诊且分娩的乙肝产妇121例，随机分为两组，妊娠中晚期使用替诺福韦酯和替比夫定分别治疗，并评估婴儿HBV感染情况和治疗安全性。结果 监测7个月龄婴儿HBV-DNA及乙肝两对半等指标。替比夫定治疗组HBsAg阳性率（%）及HBV-DNA（%）阳性率均高于使用替诺福韦的抗病毒组（%、%），但组间差异无统计学意义（P>），疗效差异不显著。%%，差异有统计学意义（χ2=，P<）。结论 妊娠晚期使用替诺福韦酯或替比夫定均可有效阻断乙肝病毒母婴传播，疗效无明显差别，但替诺福韦酯优于替比夫定，更加可靠安全。
[关键词] 替诺福韦酯;替比夫定;母婴传播;乙型肝炎病毒;疗效;安全性
[Abstract] Objective To study the efficacy and rational application of tenofovir in blocking the vertical maternal-neonatal transmission of hepatitis B virus （HBV）. Methods 121 cases of hepatitis B pregnant women were convenient selected for gynecology and obstetrics from December 2015 to December 2018， and were randomly divided into two groups. Tenofovir and tibivudine were used in the middle and late stages of pregnancy respectively， and the status and safety of HBV infection in infants were assessed. Results The indicators of HBV-DNA and hepatitis B were measured in July infants. The positive rates of HBsAg（ %） and HBV-DNA（ %） in the tibivudine treatment group were higher than those of the antiviral group using tinofovir（%， %）， but the difference between groups was not statistically significant （P>）. There was no significant difference in efficacy. The incidence of adverse reactions in the tenofovir disoproxil group was %， which was significantly lower than the % in the tenbivudine group. The difference was statistically significant （χ2=， P<）. Conclusion The use of tenofovir or tibivudine in late pregnancy can effectively block the mother-to-child transmission of hepatitis B virus. There is no significant difference in curative effect， but tenofovir is superior to tibivudine and is more reliable and safe.
[Key words] Tenofovir